Skip to main content
. 2015 Sep 11;10:1907–1916. doi: 10.2147/COPD.S89763

Table 3.

Included studies for curative effect and safety of vitamin D intake

Authors Publication Country year Country Design Controls Number Vitamin D dose Curative effect Safety Jadad scores References
Zendedel et al 2015 Iran Single-center, double-blind, Placebo and randomized Placebo 44 vs 44 Oral doses of 100,000 IU per month for 6 months Decreased COPD exacerbation and improved FEV1in the patients with severe COPD NA 3 41
Martineau et al 2015 UK Multicenter, double-blind, and randomized Placebo 118 vs 122 Six bimonthly oral doses of 120,000 IU Effective against moderate or severe exacerbation in COPD patients with 25(OH)D deficiency No serious adverse event 5 38
Bjerk et al 2013 USA Single center and pilot randomized Placebo 18 vs 18 Oral doses of 2,000 IU daily for 6 weeks No discernible effect on a simple measure of physical performance NA 1 40
Hornikx et al 2012 Belgium Double-blind and randomized Placebo 25 vs 25 A monthly dose of 100,000 IU for 1 year Improvement in inspiratory muscle strength and maximal oxygen uptake NA 4 39
Lehouck et al 2012 Belgium Randomized Placebo 91 vs 91 A monthly dose of 100,000 IU for 1 year Reduced exacerbation in COPD patients with 25(OH)D deficiency Four with mild and asymptomatic hypercalcemia 4 9

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; FEV1, forced expiratory volume in 1 second; NA, not applicable.